Gemstone Biotherapeutics For Profit
StemBioSys develops proprietary stem cell technologies for the regenerative medicine market.
Last Funding Type:
Post-IPO Equity
Headquarters:
United States
Investors Number:
5
Technology:
Other
Industry:
Regenerative medicine
Estimated Revenue:
$10M to $50M
Total Funding:
$69.9M